There have been several reports that statin therapy is associated with a slightly higher incidence of new-onset diabetes mellitus(DM) or impaired glucose intolerance(IGT). It is still controversial whether the chronic statin therapy is a risk factor of IGT and new onset DM, in Asian population.

We investigated the 13,561 patients(pts) that was HbA1c level <6.0% and fasting glucose level <124 mg/dL(statin therapy group=4016 and control group=9545). To adjust potential confounders including age, gender, hypertension, hyperlipidemia, chronic kidney disease, hyper/hypo-thyroidism, lipid profile, beta-blocker, diuretics, a propensity score matched analysis was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired fasting glucose(IFG). Also, Multivariable Cox-regression analysis adjusted aforementioned variables was performed to determine the impact of statin therapy on the incidence of new-onset DM, IGT, and IFG.

Mean follow-up duration was 534±604 days in all group, and 608±607 days in propensity score matching group. Baseline characteristics was similar between the two groups except hyperlipidemia (11.1% vs. 3.5%, p<0.001). In Kaplan-Meyer curve, there was no difference between the two groups (p=0.501, 3 A). Also, in cox-regression analysis performed in all pts, statin therapy was not associated with the increased incidence of primary end-point(3 B).

In our study, there was no clear association with statin therapy and IGT and new-onset DM in a series of cardiovascular pts in Asian population.